Systemic and Splanchnic Lipopolysaccharide and Endothelin-1 Plasma Levels in Liver Cirrhosis before and after Transjugular Intrahepatic Portosystemic Shunt

Gastroenterology Research and Practice

Volumn 2016, Issue , 2016, Pages

  Meng, Jiaxiang ^a   Wang, Qing ^b   Liu, Kai ^a   Yang, Shuofei ^a   Fan, Xinxin ^a   Liu, Baochen ^a   He, Changsheng ^a   Wu, Xingjiang ^a  

^a MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ENDOTHELIN 1; LAXATIVE; LIPOPOLYSACCHARIDE; NITRIC OXIDE;

ADULT; ANTIBIOTIC PROPHYLAXIS; ARTICLE; ASCITES; BACTERIAL TRANSLOCATION; CARBOHYDRATE ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; DIET THERAPY; ENDOTOXEMIA; ESOPHAGUS VARICES BLEEDING; FEMALE; FOLLOW UP; HEPATIC ENCEPHALOPATHY; HUMAN; LIVER CIRRHOSIS; MALE; POLITEF IMPLANT; PORTAL HYPERTENSION; PROTEIN BLOOD LEVEL; SPLANCHNIC BLOOD FLOW; SYSTEMIC CIRCULATION; TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT;

EID: 84959423333     PISSN: 16876121     EISSN: 1687630X     Source Type: Journal    
DOI: 10.1155/2016/8341030     Document Type: Article

References (18)

1. M. Fernandez, "Molecular pathophysiology of portal hypertension," Hepatology, vol. 61, no. 4, pp. 1406-1415, 2015.
2. G. Szabo, "Gut-liver axis in alcoholic liver disease," Gastroenterology, vol. 148, no. 1, pp. 30-36, 2015.
3. C. J. Steib, J. Schewe, and A. L. Gerbes, "Infection as a trigger for portal hypertension," Digestive Diseases, vol. 33, no. 4, pp. 570-576, 2015.
4. D. C. Rockey, "Endothelial dysfunction in advanced liver disease,"The American Journal of the Medical Sciences, vol. 349, no. 1, pp. 6-16, 2015.
5. T. D. Boyer and Z. J. Haskal, "The Role of Transjugular Intrahepatic Portosystemic Shunt (TIPS) in the management of portal hypertension: update 2009," Hepatology, vol. 51, no. 1, article 306, 2010.
6. B. Wen, J. Liang, X. Deng, R.Chen, and P. Peng, "Effect of fluid shear stress on portal vein remodeling in a rat model of portal hypertension,"Gastroenterology Research and Practice, vol. 2015, Article ID 545018, 7 pages, 2015.
7. Z. J.Haskal, L.Martin, J. F.Cardella et al., "Quality improvement guidelines for transjugular intrahepatic portosystemic shunts," Journal of Vascular and Interventional Radiology, vol. 14, no. 9, part 2, pp. S265-S270, 2003.
8. A. M. Miller, M. Masrorpour, C. Klaus, and J. X. Zhang, "LPS exacerbates endothelin-1 induced activation of cytosolic phospholipase A2 and thromboxane A2 production from Kupffer cells of the prefibrotic rat liver," Journal of Hepatology, vol. 46, no. 2, pp. 276-285, 2007.
9. J. Trebicka, A. Krag, S. Gansweid et al., "Endotoxin and tumor necrosis factor-receptor levels in portal and hepatic vein of patients with alcoholic liver cirrhosis receiving elective transjugular intrahepatic portosystemic shunt," European Journal of Gastroenterology and Hepatology, vol. 23, no. 12, pp. 1218-1225, 2011.
10. R. Jalan, S. W. M. Olde Damink, J. C. ter Steege et al., "Acute endotoxemia following transjugular intrahepatic stent-shunt insertion is associatedwith systemic and cerebral vasodilatation with increased whole body nitric oxide production in critically ill cirrhotic patients," Journal of Hepatology, vol. 54, no. 2, pp. 265-271, 2011.
11. D. Benten, J. S. zur Wiesch, K. Sydow et al., "The transhepatic endotoxin gradient is present despite liver cirrhosis and is attenuated after transjugular portosystemic shunt (TIPS),"BMC Gastroenterology, vol. 11, article 107, 2011.
12. T. Reiberger, A. Ferlitsch, B. A. Payer et al., "Non-selective betablocker therapy decreases intestinal permeability and serum levels of LBP and IL-6 in patients with cirrhosis," Journal of Hepatology, vol. 58, no. 5, pp. 911-921, 2013.
13. J. G. Abraldes, Y. Iwakiri, M. Loureiro-Silva, O. Haq, W. C. Sessa, and R. J. Groszmann, "Mild increases in portal pressure upregulate vascular endothelial growth factor and endothelial nitric oxide synthase in the intestinal microcirculatory bed, leading to a hyperdynamic state," The American Journal of Physiology-Gastrointestinal and Liver Physiology, vol. 290, no. 5, pp. G980-G987, 2006.
14. Y. Matsushita, Y. Narahara, S. Fujimori et al., "Effects of transjugular intrahepatic portosystemic shunt on changes in the small bowel mucosa of cirrhotic patients with portal hypertension," Journal of Gastroenterology, vol. 48, no. 5, pp. 633-639, 2013.
15. U. Wereszczynka-Siemiatkowska, A. Swidnicka-Siergiejko, A. Siemiatkowski et al., "Endothelin 1 and transforming growth factor-1 correlate with liver function and portal pressure in cirrhotic patients," Cytokine, vol. 76, no. 2, pp. 144-151, 2015.
16. E. R. Levin, "Endothelins," The New England Journal of Medicine, vol. 333, no. 6, pp. 356-363, 1995.
17. H. Kawanaka, T. Akahoshi, N. Kinjo et al., "Effect of laparoscopic splenectomy on portal haemodynamics in patients with liver cirrhosis and portal hypertension," British Journal of Surgery, vol. 101, no. 12, pp. 1585-1593, 2014.
18. R. Wiest, M. Lawson, and M. Geuking, "Pathological bacterial translocation in liver cirrhosis," Journal of Hepatology, vol. 60, no. 1, pp. 197-209, 2014.